313369-26-5

Usage

Uses

Since the specific chemical properties and potential applications of (6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3‘,4’:4,5]-pyrrolo[1,2,3-de]quinoxaline-8-carboxylate are not mentioned in the provided information, it is not possible to list its uses based on the materials given. Further research and information would be required to determine its applications in various industries.

Upstream product

• 1059630-13-5 (4aS,9bR)-6-bromo-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole (S)-(+)-mandelic acid salt 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 2098497-32-4 (4aS,9bR)-ethyl 6-bromo-5-(2-(methylamino)-2-oxoethyl)-1,3,4,4a,5,9b-hexahydro-2H-pyrido[4,3-b]indole-2-carboxylate 
• 1059630-08-8 (4aS,9bR)-ethyl 6-bromo-3,4,4a,5-tetrahydro-1H-pyrido[4,3-b]indole-2(9bH)-carboxylate 
• 1059630-07-7 [4aS,9bR]-6-bromo-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole 
• 1059630-12-4 racemate 6-bromo-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole 
• 1059630-11-3 6-bromo-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloric acid salt 
• 40064-34-4 piperidine-4,4-diol hydrochloride 
• 50709-33-6 2-bromophenylhydrazine hydrochloride 
• 313369-25-4 (6bR,10aS)-ethyl 2,3,6b,9,10,10a-hexahydro-3-methyl-2-oxo-1H-pyrido[3‘,4’:4,5]-pyrrolo[1,2,3-de]quinoxaline-8-carboxylate 

Downstream Products

• 313368-85-3 (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido-[3’,4’:4,5]-pyrrolo[1,2,3-de]quinoxaline 
• 313368-91-1 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido-[3’,4’:4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 1187020-80-9 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt 

Relevant academic research and scientific papers

Asymmetric hydrogenation method for constructing lumeperon intermediate and lumeperon intermediate

The present invention is suitable for the field of pharmaceutical synthesis technology, provides an asymmetric hydrogenation method for constructing Lumeperon intermediate and Lumeperon intermediate, the present invention using Ir- ZhaoPhos catalyzed asymmetric hydrogenation to obtain chiral compound 2, enantiomer selectivity, high conversion efficiency (S / C = 5000-10000), high yield, mild reaction conditions, conducive to reducing costs, and then the chiral compound 2 and N- methyl-2-chloroethylamine hydrochloride N- alkylation reaction to compound 3 , and then under strong alkaline conditions cyclization to obtain Lumeperon intermediate 4, less process steps, high synthesis efficiency, more conducive to industrial production.

Preparation method of Lumateperone intermediate

The invention discloses a preparation method of a Lumateperone intermediate. The Lumateperone intermediate (6bR, 10aS)-2, 3, 6b, 9, 10, 10a-hexahydro-3-methyl-1H-pyridine[3', 4':4, 5] pyrrolo [1, 2, 3-de] quinoxaline-8 (7H) carboxylic acid ethyl ester is

SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS

The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.

SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS

The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycl fused gamma-carbolines.

Substituted heterocycle fused gamma-carbolines

The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.